To orient the reader, we have summarized (Table 1) the properties of CK1 inhibitors that were used in the initial studies that established the potential of CK1 inhibition in lymphoma and leukemias described later in Section 4 and Section 5. This evidence concerns the gene CSNK1A1 and leukemia.